ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Apr 2020
Last Updated on 01 Apr 2020
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
  • Epoprostenol (Veletri) 1.5 mg powder for solution for infusion for treating idiopathic or heritable pulmonary arterial hypertension (PAH) or PAH associated with connective tissue diseases, in patients with WHO Functional Class III–IV symptoms.

Subsidy status
Epoprostenol 1.5 mg powder for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.

MAF assistance does not apply to Veletri 0.5 mg vial or Flolan 0.5 mg and 1.5 mg vials.

Epoprostenol for PAH (1 Apr 2020) PES Epoprostenol for treating pulmonary arterial hypertension (Published 1 April 2020)